Rationale This review attempts to summarize the current status in relation to the use of
positron emission tomography (PET) imaging in the assessment of synaptic concentrations of …

… Samples were drawn every 10 s for the first 90 s and at 1.75, 2, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8,
10, 15, 20, 25, 30, 45, 60, 75, 90, 105, and 120 min after [ 11 C]UCB-J injection. For each …

… and psychiatric symptoms in Huntington’s disease. Neuroscience. 2013;251:66-74. … s
disease and Parkinson’s disease human brains. J Neurodegener Dis. 2014;2014:938530. …

… Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid
… Dr Finnema was supported by an international postdoctoral grant from the Swedish …

Synaptic loss and deficits in functional connectivity are hypothesized to contribute to symptoms
associated with major depressive disorder (MDD) and post-traumatic stress disorder (…

Synaptic vesicle glycoprotein 2A (SV2A) is ubiquitously present in presynaptic terminals.
Here we report kinetic modeling and test–retest reproducibility assessment of the SV2A …

Alzheimer’s disease (AD) affects more than 35 million people worldwide, and the number is
estimated to quadruple in 40 years if there remains no cure. 1–4 AD is characterized by the …

Objective Parkinson disease is characterized by motor and nonmotor symptoms, reduced
striatal dopamine signaling, and loss of dopamine neurons in the substantia nigra. It is now …

… Samples were drawn every 10 s for the first 90 s and at 1.75, 2, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8,
10, 15, 20, 25, 30, 45, 60, 75, 90 min after [ 11 C]UCB-J injection. For each sample, plasma …

[ 11 C]UCB-J PET for synaptic vesicle glycoprotein 2 A (SV2A) has been proposed as a
suitable marker for synaptic density in Alzheimer’s disease (AD). We compared [ 11 C]UCB-J …